Gene Editing Breakthroughs Transform Cancer and Disease Treatment Approaches

Molecular insights have transformed treatment development in inflammatory skin diseases, but clinicians still lack reliable tools to match therapies to individual patients.

A single gene-editing treatment could someday protect against heart disease, high cholesterol, and other common conditions for decades, potentially replacing lifelong medications. But scientists [···]

Nov 3 (Reuters) - Nurix Therapeutics said on Tuesday that Sanofi has decided to discontinue development of an experimental treatment for autoimmune and inflammatory diseases, eliminating potential [···]

A new molecular map of breast cancer has identified novel forms of the disease and provides a foundation for selecting personalized treatments guided by a tumor's molecular characteristics rather [···]

In this non-randomised registry analysis of patients with left main coronary artery disease, there was no statistically detectable difference in all-cause mortality between PCI and CABG. For [···]

A targeted immunoPET scan detected active multiple myeloma that standard PET/CT scans and blood tests missed, a finding that could help doctors more accurately map disease, guide treatment decisions [···]

A new molecular map of breast cancer has identified novel forms of the disease and provides a foundation for selecting personalized treatments guided by a tumor's molecular characteristics rather [···]

Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease in which persistent mucosal inflammation damages the epithelial barrier.

A targeted immunoPET scan detected active multiple myeloma that standard PET/CT scans and blood tests missed, a finding that could help doctors more accurately map disease, guide treatment decisions [···]

SAN DIEGO Bemdaneprocel had a favorable safety profile over 4 years of treatment among patients with Parkinson's disease, according to a poster presented at the 151st Annual Meeting of the American [···]

The USA's Institute for Clinical and Economic Review (ICER) today released a Final Evidence Report assessing the comparative clinical effectiveness and value of Juvmo (tavapadon) from US pharma [···]

Speakers at the Breakthrough T1D Clinical & Research Congress 2026 debate the future of type 1 diabetes treatment.

Abbott's Tectonic test looks to shift artery disease treatment with 'early' win

A monthly 300 mg dose of ianalumab demonstrated greater reductions in disease activity vs. placebo at 48 weeks among patients with Sjögren's disease, according to data from two trials published in [···]

Swiss pharma major Novartis has ended a collaboration with Swedish biotech company BioArctic aimed at developing a potential brain-penetrant treatment for neurodegenerative disease.

Scientists have discovered that a drug originally developed for spinal cord injuries can tackle several key features of Alzheimer's disease, including DNA damage and inflammation. Already tested [···]